SecBot SecBot
Biotech Drug Report Generated Nov 15, 2026

ARO-MAPT

ARWR·ARROWHEAD PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1/2a
Time to market
At least 4-6 years away from potential approval if successful. The drug is in Phase 1/2a, Part 2 (Alzheimer's patients) is enrolling, and additional larger trials would be needed before any regulatory filing.
Why 4/10
The next hard, dated catalyst is Part 2 of the Phase 1/2a study in Alzheimer's patients, but no firm readout date has been provided and it is likely 12+ months away. ARO-MAPT is an early-stage (Phase 1/2a) asset at a company with multiple late-stage cardiometabolic programs (plozasiran, ARO-DIMER-PA) and a marketed product (REDEMPLO), so this single drug is not a make-or-break binary for the stock in the next 12 months.
Actionable Insight NEUTRAL

The next catalyst for ARO-MAPT is Part 2 of the ongoing Phase 1/2a study, which is enrolling patients with Alzheimer's disease and other tauopathies. No firm readout date has been given, but given healthy-volunteer enrollment began in early 2026, patient data could emerge in late 2027 or 2028. Part 2 data showing tau reduction translates to cognitive or functional benefit would be a major positive for the TRiM CNS platform; failure to differentiate from Biogen/Ionis' diranersen or a poor safety signal in patients would be a setback.

Price Chart

Loading chart...

Executive Summary

ARO-MAPT is Arrowhead Pharmaceuticals' investigational RNAi therapy targeting the MAPT gene to reduce tau protein production as a potential treatment for Alzheimer's disease and other tauopathies. In October 2026, interim Phase 1/2a data showed up to 73% reduction in cerebrospinal fluid tau in healthy volunteers with a favorable safety profile across three dose levels. The drug uses Arrowhead's TRiM platform for subcutaneous delivery across the blood-brain barrier. Part 2 of the study is enrolling patients with Alzheimer's disease, but no readout date has been given. While the early data is encouraging, ARO-MAPT is an early-stage asset at a company with multiple later-stage programs, and the tau-lowering field now includes Biogen/Ionis' diranersen, which posted positive Phase 2 data in July 2026. The stock has fallen from ~$87 to ~$47 in recent months despite the positive data.

How It Works

ARO-MAPT is an RNA interference (RNAi) therapy that silences the MAPT gene, which provides the instructions for making tau protein. Tau proteins can clump together in the brain to form tangles, a hallmark of Alzheimer's disease and other neurodegenerative disorders called tauopathies. By reducing tau production at the genetic level, ARO-MAPT aims to slow or prevent disease progression. It uses Arrowhead's TRiM (Targeted RNAi Molecule) platform to be delivered subcutaneously (under the skin) and designed to cross the blood-brain barrier to reach its target in the central nervous system.

Trial Status

An ongoing Phase 1/2a study (NCT07221344) is evaluating ARO-MAPT in healthy volunteers and patients with Alzheimer's disease or other tauopathies. Interim data from the healthy volunteer portion (Part 1) was released in October 2026, showing dose-dependent, deep, and durable CSF tau reductions (up to 73%) with a favorable safety profile. Part 2, which enrolls Alzheimer's patients, is actively recruiting. The study was initiated in late 2025 following preclinical data presented at the RNA Leaders USA Congress 2025.

The Two-Sided Case

▲ Bull Case4
Interim Phase 1/2a data showed up to 73% reduction in cerebrospinal fluid tau in healthy volunteers across three dose levels (2.1, 6.4, and 12.8 mg/kg), described as deep and durable with no serious adverse events a positive early safety signal.
ARO-MAPT uses Arrowhead's TRiM platform for subcutaneous delivery across the blood-brain barrier, a key differentiator versus the intrathecal delivery required by Biogen's diranersen, potentially offering a more convenient administration route.
Analyst consensus is strongly bullish: 20 buy/strong buy ratings, 1 hold, 0 sell, with a mean price target of ~$106 (122% implied upside from ~$47.78). Morgan Stanley added to its position (+69%) in Q3 2026.
The TRiM CNS platform, if validated in patients, could be leveraged for multiple CNS targets beyond tau, creating pipeline-in-a-product optionality.
▼ Bear Case4
Part 2 of the Phase 1/2a study in Alzheimer's patients has no firm readout date and could take 12-24 months. Clinical validation in patients (not just healthy volunteers) is unproven.
The tau-lowering space is increasingly competitive: Biogen/Ionis' diranersen (an antisense oligonucleotide) posted positive Phase 2 CELIA data in July 2026 showing tau reduction and cognitive signals at AAIC 2026, setting a high bar.
ARWR stock has fallen sharply from ~$87 in August 2026 to ~$47 in November 2026 despite positive data, with notable insider sales (~$1M by director Perry and ~$174K by director Olukotun both in August) and several institutional exits/trims in Q3 2026, including complete exits by 1832 Asset Management and HRT Financial.
Arrowhead reported FY2026 revenue of $444M (down 46% YoY from $829M) and a net loss of $5.11 per share, reflecting the post-Sarepta payment normalization and heavy R&D spend.

Upcoming Catalysts

  • Part 2 Phase 1/2a data in Alzheimer's disease patients (no firm date announced, likely 12+ months away)
  • Possible pipeline updates from Arrowhead R&D events or scientific conferences

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ARROWHEAD PHARMACEUTICALS, INC. 8-K ARWR ·Originating report

Sources · 10

Hover a chip for the title
1 businesswire.com2 morningstar.com3 bioworld.com4 seekingalpha.com5 msn.com6 businesswire.com7 seekingalpha.com8 seekingalpha.com9 morningstar.com10 sec.gov